Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 3. Details of Included Studies

Study No.

First Author, Year

Phase

Report Type

Quality

Comments

Imatinib Efficacy Studies

1

van Oosterom, 20016

I/II

Full report

3/5

Main results

1

van Oosterom, 200245

III

Full report

3/5

Followup efficacy data for van Oosterom, et al. 2001

2

Demetri, 200246

II

Full report

5/5

Main results

2

Dagher 200243

II

Full report

5/5

FDA approval summary with review of Demetri, et al. 2002 data

2

Heinrich, 200347

II

Full report

6/6

followup efficacy data for Demetri, et al. 2002

3

Verweij, 200348

II

Full report

6/6

Main results

4

Verweij, 200449

III

Full report

6/6

Main results

4

Zalcberg, 200450

II

Abstract

Unk

Followup efficacy data for Verweij, et al. 2004

5

Casali, 200451

II

Abstract

Unk

Early results of phase II trial

6

Blay, 200452

III

Abstract

Unk

Early results of phase III trial

7

Rankin, 200453

III

Abstract

Unk

Early results of phase III trial

7

Patel, 200354

III

Abstract (published 2003 abstract plus commentary)

Unk

Early results of Rankin, et al. 2004 Phase III trial

Imatinib Plus Surgery Efficacy Studies

8

Bumming, 200355

II

Full report

4/6

Main results

9

Rutkowski, 200356

Retro

Full report

1/6

Main results

10

Scaife, 200357

Retro

Full report

2/5

Main results

11

Wu, 200358

Retro

Full report

1/6

Main results

Adverse Events/harm

1

van Oosterom, 20016

I/II

Full report

3/5

Adverse event data reported within main results full report

1

van Oosterom, 200245

III

Full report

3/5

followup adverse event data for van Oosterom, et al. 2001

2

Demetri, 200246

II

Full report

5/5

Adverse event data reported within main results full report

2

Dagher 200243

II

Full report

5/5

FDA approval summary with review of Demetri, et al. 2002 data

3

Verweij, 200348

II

Full report

6/6

Adverse event data reported within main results full report

4

Verweij, 200449

III

Full report

6/6

Adverse event data reported within main results full report

Predictors—tumor characteristics

1

Debiec-Rychter, 200459

I/II

Full report

6/6

Molecular predictors, sub-study of van Oosterom, et al. 2001

2

Frolov, 200360

II

Full report

1/6

Molecular predictors, sub-study of Demetri, et al. 2002

2

Heinrich, 200347

II

Full report

6/6

Molecular predictors, sub-study of Demetri, et al. 2002

3

Verweij, 200348

II

Full report

6/6

Other predictors reported within main results full report

Predictors—radiological findings

1

Stroobants, 200361

I/II

Full report

4/6

Radiological predictors, sub-study of van Oosterom, et al. 2001

12

Antoch, 200462

Pros

Full report

5/5

Radiological predictors study

13

Gayed, 200463

Pros

Full report

1/5

Radiological predictors study

14

Di Giorgi, 200464

Pros

Abstract

Unk

Radiological predictors study

15

Laussau, 200465

Pros

Abstract

Unk

Radiological predictors study

Predictors—other clinical factors

2

Heinrich, 200347

II

Full report

6/6

Other predictors, sub-study of Demetri, et al. 2002

4

Verweij, 200449

III

Full report

6/6

Other predictors reported within main results full report

Abbreviations:  Retro = retrospective; Unk = unknown; Pros = prospective

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care